Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

Status unconfirmed · Phase 2 · Has a placebo group

Conditions studied: Non Alcoholic Steatohepatitis (NASH)

In brief

This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.

Key facts

Study ID
NCT04880187
Run by
Axcella Health, Inc
People needed
273
Starts
2021-05-07
Expected to finish
2023-10-01
Last updated by the study team
2022-09-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.